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GSK3βThe biologically active factors known as adipocytokines are secreted primarily by adipose tissues and can act
as modulators of angiogenesis. Visfatin, an adipocytokine that has recently been reported to have angiogenic
properties, is upregulated in diabetes, cancer, and inﬂammatory diseases. Because maintenance of an
angiogenic balance is critically important in the management of these diseases, understanding the molecular
mechanism by which visfatin promotes angiogenesis is very important. In this report, we describe our
ﬁndings demonstrating that visfatin stimulates the mammalian target of the rapamycin (mTOR) pathway,
which plays important roles in angiogenesis. Visfatin induced the expression of hypoxia-inducible factor 1α
(HIF1α) and vascular endothelial growth factor (VEGF) in human endothelial cells. Inhibition of the mTOR
pathway by rapamycin eliminated the angiogenic and proliferative effects of visfatin. The visfatin-induced
increase in VEGF expression was also eliminated by RNA interference-mediated knockdown of the 70-kDa
ribosomal protein S6 kinase (p70S6K), a downstream target of mTOR. Visfatin inactivated glycogen synthase
kinase 3β (GSK3β) by phosphorylating it at Ser-9, leading to the nuclear translocation of β-catenin. Both
rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3β phosphorylation at Ser-9
and nuclear translocation of β-catenin. Taken together, these results indicate that mTOR signaling is involved
in visfatin-induced angiogenesis, and that this signaling leads to visfatin-induced VEGF expression and
nuclear translocation of β-catenin.82 2 388 0924.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Obesity is strongly linked to diabetes mellitus and several other
metabolic and cardiovascular disorders [1]. Recently, adipose tissue has
emerged as an endocrine organ that is the primary producer of
adipocytokines, a group of secreted, biologically active growth factors
and cytokines that include adiponectin, interleukin-6, leptin, and visfatin
(pre-B-cell colony-enhancing factor; PBEF) [2]. These adipocytokines
have various biological functions and can have cardiovascular effects [3].
Visfatin was originally cloned from human peripheral blood
lymphocytes and characterized as nicotinamide phosphoribosyltrans-
ferase (Nampt), an enzyme that synthesizes nicotinamide mononu-
cleotide from nicotinamide [4,5]. Subsequently, it was recognized as
an adipocytokine preferentially produced by visceral fat and renamed
visfatin. Interestingly, visfatin has been reported to have insulin-
mimetic effects in various cultured cell lines and in insulin-sensitive
tissues, although these effects remain controversial [6,7].Several recent studies have suggested that visfatin has angiogenic
properties [8–11]. Angiogenesis, the process of new blood vessel
formation from existent vasculature, is important not only in tissue
homeostasis, embryonic development, and wound healing but also in
some pathologic conditions, including tumor growth, diabetes, and
inﬂammation [12]. Angiogenesis is also important as a therapeutic
target for myocardial infarction, ischemic stroke, and other ischemic
conditions.
Several studies have shown that visfatin levels are elevated in
diabetes, cancer, and inﬂammatory disease [13–16]. Visfatin activates
Akt (the serine/threonine protein kinase B) and induces the
expression of vascular endothelial growth factor (VEGF) in human
endothelial cells [9]. However, the precise downstream signaling
mechanism underlying these effects and its ability to induce
angiogenesis are not yet fully understood. Since maintaining
angiogenic homeostasis is very important in preventing the progres-
sion of these diseases, understanding the molecular mechanisms by
which visfatin promotes angiogenesis is an important research goal.
The serine/threonine kinase known as mTOR (mammalian target
of rapamycin) is a critical regulator of cellular proliferation and
metabolism. The mTOR pathway integrates the signals of various
factors, including Ras, Akt, and NF-κB, that respond to nutrients,
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signaling is frequently associated with tumor growth, metastasis, and
angiogenesis [17]. Rapamycin, an inhibitor of the mTOR pathway, is
used clinically for anticancer therapy and to prevent stent restenosis
[18].
In the present study, we investigated the possible involvement of
the mTOR signaling pathway in visfatin-induced angiogenesis and
characterized the downstream molecular effectors of visfatin. Our
data show for the ﬁrst time that visfatin induces angiogenesis in
human endothelial cells via activation of the mTOR pathway. They
also demonstrate that activation of themTOR pathway increases VEGF
protein expression and β-catenin nuclear translocation by inactivat-
ing glycogen synthase kinase 3β (GSK3β).2. Materials and methods
2.1. Materials
Recombinant visfatin and a phosphoinositide 3 (PI3)-kinase
inhibitor, LY294002 were purchased from Peprotech (Rocky Hill, NJ)
and Calbiochem (San Diego, CA), respectively. Visfatin protein used in
this study was N98% pure (SDS-PAGE analysis) and contained 0.01 ng/
μg LPS as determined by the Limulus amebocyte lysate similar to the
previous study [19]. Rapamycin, differentiation inducing factor-3
(DIF-3), lithium chloride (LiCl), and a speciﬁc competitive inhibitor of
visfatin, FK866 were purchased from Sigma (St Louis, MO). Recom-
binant human VEGF was from R&D Systems (Minneapolis, MN).
Growth factor-reduced Matrigel was purchased from BD Biosciences
(San Jose, CA). The primary antibodies used in this study were speciﬁc
for Ser-473-phosphorylated Akt, Ser-2448-phosphorylated mTOR,
Ser-9-phosphorylated GSK3β, Thr-389-phosphorylated 70-kDa ribo-
somal protein S6 kinase (p70S6K), Ser-241-phosphorylated phos-
phoinositide-dependent kinase-1 (PDK1), HIF1α (Cell Signaling
Technology, Beverly, MA), VEGF (R&D Systems), β-catenin (BD
Biosciences), cyclin D1 (BD Biosciences), visfatin (Phoenix Pharma-
ceuticals, Belmont, CA), and β-actin (Sigma).2.2. Cell culture
Human umbilical vein endothelial cells (HUVECs; Clonetics,
Walkersville, MD) at passages 3–6 were grown in SingleQuots
endothelial cell growth medium-2 (EGM-2; Clonetics) at 37 °C in a
humidiﬁed 5%-CO2 atmosphere. The medium was replaced with
endothelial cell basal medium-2 (EBM-2; Clonetics) supplemented
with 0.1% fetal bovine serum (FBS) 5 h before all experimental
treatments, with the exception of tube formation and aortic ring-
sprouting assays.2.3. Western blotting
Cells were lysed in a lysis buffer (Cell Signaling Technology)
containing 50 mM NaF, 2 mM Na3VO4, 100 μg/ml phenylmethylsulfo-
nyl ﬂuoride, and protease inhibitor cocktail (Sigma). Protein con-
centrations in the lysate samples were determined using Bradford
Assay Reagent (Bio-Rad Laboratories, Hercules, CA) with bovine
serum albumin (BSA) as a standard. Equal amounts of cell lysates
were subjected to SDS-PAGE, and the separated proteins were
transferred to a polyvinylidene ﬂuoride membrane (Millipore, Bed-
ford, MA). The membrane was incubated with primary antibody
overnight at 4 °C and then with the appropriate secondary antibody
for 1 h at room temperature. Bands were detected using an ECL
system (Santa Cruz Biotechnology, Santa Cruz, CA). All experiments
were performed at least three times.2.4. Tube formation assay
Tube formation assays were carried out using Matrigel according
to themanufacturer's protocol (BD Biosciences). Brieﬂy, HUVECswere
cultured on the surface of the Matrigel, treated with visfatin (1 μg/ml)
in the presence or absence of rapamycin (25 nM), and the extent of
capillary tube formation 15 h after treatment was observed in three
randommicroscopic ﬁelds. As a positive control, the cells were treated
with VEGF (20 ng/ml) rather than visfatin.
2.5. Aortic ring-sprouting assay
Aortic ring-sprouting assays were performed using a protocol
modiﬁed from a previous study [20]. Each well of a 24-well plate was
coated with Matrigel, and the Matrigel was allowed to polymerize for
30 min at 37 °C. Aortas were extracted from 6-week-oldmale C57BL/6
mice, and the adipose tissue was carefully removed under a
microscope. The aortas were cut into 1-mm-thick slices, rinsed four
times with EGM-2 medium, placed on the Matrigel-coated plates, and
covered with additional Matrigel. TheMatrigel was allowed to solidify
at 37 °C, and the EGM-2 medium was added. After 24 h, the medium
was replaced with fresh EBM-2 media supplemented with 2% FBS,
ascorbic acid, hydrocortisone, heparin, and amphotericin, and visfatin,
rapamycin, and/or VEGF were added. After 4 days of incubation,
vascular sprouts from the aortic tissues were photographed. Mice
were housed and treated in accordance with the Animal Care
Guidelines of the Korean National Institutes of Health Animal Facility.
2.6. 5-bromodeoxyuridine (BrdU) incorporation assay
BrdU incorporation was assayed using a Cell Proliferation ELISA
BrdU (colorimetric) kit (Roche, Mannheim, Germany) according to
the manufacturer's instructions. Brieﬂy, HUVECs treated with visfatin
in the presence or absence of rapamycin were labeled with BrdU for
8 h, ﬁxed, and washed. Anti-BrdU-POD working solution and
substrate solutionwere added, and BrdU incorporationwas quantiﬁed
by measuring the absorbance at 370 nM on an automated ELISA
microplate reader (Molecular Devices, Sunnyvale, CA).
2.7. In vitro wound-healing migration assay
HUVECs were seeded into 12-well plates and grown to 90%
conﬂuence. Wounds were made by careful scraping of the cell layer
with sterile cell scrapers. The medium was replaced with EBM-2
media supplemented with 0.1% FBS and visfatin with or without
rapamycin. After 24 h at 37 °C, the cells were photographed, and the
cells that had migrated into the wound area were counted manually.
At least three independent experiments were performed.
2.8. Transfection of siRNA
HUVECs grown to 30% conﬂuence were transfected with p70S6K
or β-catenin siRNA (Invitrogen, Carlsbad, CA) using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer's protocol.
After 48 h, the cells were treated with visfatin. The siRNA sequences
were as follows: human p70S6K, 5′-UUC UCC UCC ACU GAG AUA CUC
AAG G-3′ (sense) and 5′-CCU UGA GUA UCU CAG UGG AGG AGA A-3′
(anti-sense); human β-catenin, 5′-UUA CCA CUC AGA GAA GGA GCU
GUG G-3′ (sense) and 5′-CCA CAG CUC CUU CUC UGA GUG GUA A-3′
(anti-sense). At a ﬁnal siRNA concentration of 50 nM, the transfection
efﬁciency was about 80% efﬁciency.
2.9. Immunocytochemical analysis
After HUVECs were cultured on four-well Lab-Tek chamber slides
(Nalge Nunc, Rochester, NY), themediumwas replacedwith the EBM-
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rapamycin. After 4 h, the cells were ﬁxed in 4% paraformaldehyde for
20 min and washed three times with phosphate-buffered saline
(PBS). The cells were permeabilized by incubation in 0.2% Triton X-
100 in PBS for 2 min, blocked with 5% BSA in PBS (5% BSA/PBS) for 1 h,
and then incubated with a mouse monoclonal antibody against
human β-catenin (1:200 in 2% BSA/PBS) or with a rabbit polyclonal
antibody against cleaved caspase-3 (1:100 in 2% BSA/PBS) overnight
at 4 °C. After three washes with PBS, the cells were incubated with
Alexa 594-conjugated goat anti-mouse secondary antibody (Invitro-
gen) or with Alexa Fluor 488-conjugated goat anti-rabbit secondary
antibody (Invitrogen) in 2% BSA/PBS. The cells were rinsed with PBS,
mounted with Vectashield mounting medium containing 4′,6-diami-
dino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA),
and imaged under a ﬂuorescence microscope.
3. Results
3.1. Visfatin activates mTOR and inactivates GSK3β
When we examined the phosphorylation of PDK1, Akt, mTOR, and
GSK3β in HUVECs grown in the presence of visfatin, Western blot
analysis with phospho-speciﬁc antibodies conﬁrmed that visfatin
increases PDK1 and Akt phosphorylation as described previously
(Fig. 1) [8,9,11]. In addition, visfatin time- and dose-dependently
increased mTOR phosphorylation at Ser-2448 and GSK3β phosphor-
ylation at Ser-9, thereby activating mTOR and deactivating GSK3β
(Fig. 1). It also time-dependently increased the total expression of β-
catenin. Because visfatin has been reported to increase VEGF
expression, and HIF1α is a key transcription factor for VEGF
transcription [21–23], we also examined the effect of visfatin on
HIF1α expression. We found that visfatin increased HIF1α expression
in a dose-dependent manner (Fig. 1B).
3.2. The mTOR signaling pathway is involved in visfatin-induced
angiogenesis in vitro and ex vivo
Our ﬁnding that visfatin induces activation ofmTOR suggested that
the mTOR signaling pathway is involved in visfatin-induced angio-
genesis. To investigate this hypothesis, we examined the effects of
rapamycin, a speciﬁc inhibitor of mTOR, on visfatin-induced angio-
genesis. First, we examined the formation of capillary-like tubes by
HUVECs plated on Matrigel. As shown in Fig. 2A, visfatin treatment
increased tube formation by the HUVECs, but rapamycin signiﬁcantly
inhibited this effect. Next, we examined the effect of rapamycin on
visfatin-induced angiogenesis in an ex vivo mouse aorta model
(Fig. 2B). Incubation of mouse aortic tissue embedded in Matrigel
with visfatin for 4 days increased microvessel sprouting from theFig. 1. Visfatin activates mTOR and inactivates GSK3β signaling pathways in HUVECs. Serum
Western blotting. Results shown are representative of at least three independent experiment
HUVECs were treated with the indicated doses of visfatin for 30 min.tissue, but the addition of rapamycin signiﬁcantly inhibited visfatin
induced-microvessel outgrowth (Fig. 2B).
We next examined endothelial cell mobility by counting the
HUVECs that migrated into a wound scratched into a conﬂuent cell
monolayer with a cell scraper. Visfatin signiﬁcantly increased the
mobility of the HUVECs, but co-treatment with rapamycin signiﬁ-
cantly inhibited this effect (Fig. 2C); in fact, it reduced cell mobility to
less than that of the control. Similarly, when we explored the HUVEC
proliferation using BrdU incorporation and MTT assays, we observed
that visfatin signiﬁcantly increased HUVEC proliferation, but co-
treatment with rapamycin signiﬁcantly inhibited this effect of visfatin
(Fig. 2D and Supplementary Fig. 1A). To explore the involvement of
apoptosis in this rapamycin-induced growth inhibition, ﬁxed HUVECs
were stained with an antibody against cleaved caspase-3 (Supple-
mentary Fig. 1B). The number of cells positive for cleaved caspase-3
did not increase signiﬁcantly after rapamycin exposure (Supplemen-
tary Fig. 1B). A terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling (TUNEL) assay yielded similar results
(data not shown). These results suggest that rapamycin does not exert
its antiproliferative and antiangiogenic effects via apoptosis.
3.3. Visfatin increases VEGF expression by affecting the mTOR signaling
pathway
Visfatin has been reported to increase VEGF expression via the Akt
signaling pathway [9]. To explore whether the visfatin-induced
expression of VEGF also involves the mTOR signaling pathway,
HUVECs were treated for 24 h with visfatin in the presence or absence
of rapamycin. When wemeasured VEGF expression and normalized it
to β-actin expression, we found that visfatin treatment increased
VEGF expression by half, and that co-treatment with rapamycin
abolished this increase (Fig. 3A). To more speciﬁcally explore the
downstream signaling mechanism, we analyzed the phosphorylation
of p70S6K, an mTOR downstream kinase, in HUVECs treated with
visfatin in the presence or absence of rapamycin for 4 h. In the absence
of rapamycin, a visfatin-induced increase in VEGF expression was
evident within 4 h, as was an increase in phosphorylation of p70S6K
at Thr-389 (Fig. 3B). These effects were eliminated by rapamycin co-
treatment. Visfatin also increased HIF1α expression in a rapamycin-
inhibitablemanner, but it increased Akt phosphorylation at Ser-473 in
a rapamycin-independent manner (Fig. 3B), suggesting that visfatin
increases VEGF expression via the mTOR signaling pathway.
To conﬁrm that mTOR signaling is involved in visfatin-induced
VEGF expression, we examined the effect of knockdown of p70S6K,
which reportedly mediates mTOR phosphorylation at Ser-2448 [24].
The increase in VEGF expression induced by incubation with visfatin
for 24 h was substantially smaller in p70S6K siRNA-transfected
HUVECs than in control siRNA-transfected cells (Fig. 3C, D).-starved HUVECs were treated with visfatin and analyzed for the indicated proteins by
s. (A) HUVECs were treated with 300 ng/ml visfatin for the indicated lengths of time. (B)
Fig. 2. Rapamycin inhibits visfatin-induced angiogenesis. (A) HUVECs were seeded on Matrigel in the presence of visfatin (1 μg/ml) with or without rapamycin (25 nM) for 15 h and
then examined for the formation of capillary-like tubes. VEGF (20 ng/ml) was used as a positive control. (B) Mouse aortic tissues were embedded into Matrigel and incubated for
4 days in the presence of visfatin (1 μg/ml) with or without rapamycin (25 nM) and then examined for visfatin-induced microvessel outgrowth. As a positive control, tissues were
incubated in EGM-2 medium for 4 days. (C) Conﬂuent HUVEC monolayers were wounded with a cell scraper, and incubated with visfatin (1 μg/ml) in the presence or absence of
rapamycin (25 nM), and assessed for cell mobility by counting the cells that had moved into the wounded area after 24 h. Values are expressed as means±SD (n=6).
(D) Endothelial cell proliferation was examined by measuring BrdU incorporation in HUVECs preincubated with rapamycin (25 nM) prior to stimulation with visfatin (1 μg/ml).
Values are expressed as means±SD (n=4). **Pb0.01, ***Pb0.001 vs control or vs visfatin- and rapamycin-treated samples using Student's t-test.
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2448 (Fig. 3D), consistent with the results of Chiang et al. [24].
3.4. The mTOR signaling pathway is involved in visfatin-induced
inactivation of GSK3β and nuclear translocation of β-catenin
Because we observed that visfatin increases the phosphorylation
of GSK3β at Ser-9 residue (Fig. 1), thereby inactivating it, and p70S6K
has been reported to regulate GSK3β phosphorylation [25], we
investigated whether the mTOR signaling pathway is involved in
visfatin-induced phosphorylation of GSK3β. After treating HUVECs
with visfatin in the absence or presence of rapamycin for 4 h, we
analyzed GSK3β phosphorylation at Ser-9 (Fig. 4A). Rapamycin
inhibited the induction of both GSK3β phosphorylation and β-
catenin expression by visfatin (Fig. 4A). Knockdown of p70S6K
expression produced effects similar to those of rapamycin treatment
(Fig. 4B).
To investigate whether visfatin promotes nuclear translocation of
β-catenin, we examined the cytoplasmic and nuclear fractions of
HUVECs incubated with visfatin in the presence or absence of
rapamycin. Visfatin treatment increased β-catenin levels in the
nuclear extracts, but co-treatment with rapamycin reduced themagnitude of this increase (Fig. 4C), as did p70S6K knockdown
(Fig. 4D). Immunocytochemical analysis conﬁrmed that visfatin
promotes β-catenin nuclear translocation and that this effect of
visfatin is inhibited by rapamycin (Fig. 4E). These results indicate
that the mTOR signaling pathway is involved in visfatin-induced
GSK3β inactivation and β-catenin nuclear translocation.
3.5. β-catenin is involved in visfatin-induced angiogenesis
To explore the role of β-catenin in visfatin-induced angiogen-
esis, we used RNA interference to knock down β-catenin
expression in HUVECs. β-catenin knockdown signiﬁcantly inhib-
ited the visfatin-induced migration of HUVECs (Fig. 5A). Because
β-catenin induces the expression of cyclin D1, which acts as a
mitogenic signal sensor [26], we next investigated whether
knockdown of β-catenin would affect cyclin D1 expression in
visfatin-treated HUVECs. Visfatin treatment signiﬁcantly in-
creased the expression of cyclin D1 in control cells but not in
β-catenin siRNA-transfected cells (Fig. 5B). In addition, β-catenin
knockdown nearly eliminated the visfatin-induced expression of
VEGF (Fig. 5B) and inhibited the visfatin-induced formation of
capillary-like tubes by HUVECs seeded on Matrigel beds (Fig. 5C).
Fig. 3.Western blot analysis of visfatin-treated HUVECs shows that themTOR signaling pathway is involved in visfatin-induced expression of VEGF. (A) HUVECs were incubated with
visfatin (300 ng/ml) in the presence or absence of rapamycin (25 nM) for 24 h and assessed for VEGF expression andmTOR phosphorylation at Ser-2448 byWestern blotting. Values
are expressed as means±SD (n=4). *Pb0.05, **Pb0.01 using Student's t-test. (B) HUVECs were incubated with visfatin (300 ng/ml) in the presence or absence of rapamycin
(25 nM) or with CoCl2 (400 μM) for 4 h and assessed for expression of VEGF and HIF1α and for phosphorylation of mTOR (Ser-2448), Akt (Ser-473), and p70S6K (Thr-389) by
Western blotting. Results shown are representative of at least three independent experiments. (C) HUVECs transfected with control siRNA or p70S6K siRNA were treated with or
without visfatin (300 ng/ml) for 24 h and assessed for VEGF expression and p70S6K phosphorylation at Thr-389 by Western blotting. Values are expressed as means±SD (n=4).
*Pb0.05, **Pb0.01 using Student's t-test. (D) HUVECs transfected with control siRNA or p70S6K siRNA were treated with or without visfatin (300 ng/ml) for 4 h and assessed for
p70S6K phosphorylation at Thr-389 and mTOR phosphorylation at Ser-2448 by Western blotting. Results shown are representative of at least three independent experiments.
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addition of rapamycin to β-catenin siRNA-transfected HUVECs
(Fig. 5C). These results suggest that β-catenin and mTOR play key
roles in visfatin-induced angiogenesis.3.6. Akt acts upstream of mTOR and GSK3β signaling
Both PDK1 and Akt bind directly to phosphatidylinositol (3,4,5)-
trisphosphate [PtdIns(3,4,5)P3] and phosphatidylinositol (3,4)-
Fig. 4. Western blot (A–D) and immunocytochemical (E) analyses showing that the mTOR signaling pathway is involved in visfatin-induced inactivation of GSK3β and nuclear
translocation of β-catenin. (A, C, and E) HUVECs were incubated with visfatin (300 ng/ml) in the presence or absence of rapamycin (25 nM) for 4 h. (B and D) HUVECs transfected
with control siRNA or p70S6K siRNA were incubated with visfatin (300 ng/ml) for 4 h. (A and B) GSK3β phosphorylation at Ser-9 was analyzed by Western blotting. (C and D) The
cytoplasmic and nuclear fractions were separated, and β-catenin translocation into the nucleus was analyzed by Western blotting. Lamin A/C and β-actin were faintly detected in
cytoplasmic and nuclear fractions, respectively (data not shown). (E) After the cells were ﬁxed and permeabilized, they were incubated with mouse anti-β-catenin antibody and
then with Alexa 594-conjugated anti-mouse antibody (red). Nuclei were counter-stained with DAPI (blue). The cells were imaged under a ﬂuorescence microscope at 400×. In A–E,
the results shown are representative of at least three independent experiments.
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kinase and are restricted to the plasma membrane. Therefore,
activation of PI3-kinase causes PDK1 and Akt to translocate to the
plasma membrane, where activated PDK1 phosphorylates and
activates Akt [27]. Therefore, when we observed that visfatin induces
the phosphorylation of PDK1 and Akt (Fig. 1), we next investigatedthe effect of visfatin-induced activation of Akt on mTOR and GSK3β
using LY294002, an inhibitor of PI3-kinase (Fig. 6). Pretreatment of
HUVECs with this inhibitor attenuated visfatin-induced mTOR
activation and GSK3β inactivation. In addition, LY294002 pretreat-
ment abolished visfatin-induced β-catenin expression. These results
suggest that PI3-kinase and Akt act upstream of mTOR and GSK3β.
Fig. 5. Knockdown of β-catenin expression by siRNA infection inhibits visfatin-induced angiogenesis. HUVECs were transfected with control or β-catenin siRNA for 48 h and analyzed
for mobility (A); expression of β-catenin, cyclin D1, and VEGF (B); and the effect of rapamycin on microvessel outgrowth. (A) After conﬂuent transfected HUVEC monolayers were
wounded with a cell scraper, the cells were incubated with or without visfatin (1 μg/ml) for 24 h, and the cells that migrated into the wounded area were counted. Values are
expressed as means±SD (n=4). *Pb0.05, ** Pb0.01 using Student's t-test. (B) Transfected HUVECs were treated with visfatin (300 ng/ml) for 24 h and analyzed for expression of
the indicated proteins by Western blotting. (C) Transfected HUVECs were detached using trypsin-EDTA, seeded on Matrigel beds, and incubated with visfatin (1 μg/ml) in the
presence or absence of rapamycin (25 nM) for 15 h. and assessed for microvessel outgrowth. In A–C, the results shown are representative of at least three independent experiments.
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Visfatin plays important roles in angiogenesis, acting through
several different mechanisms [8–11,28]. It up-regulates the expres-
sion of VEGF, VEGF receptor 2 (VEGF-R2), and endothelial nitric oxide
synthase by activating the mitogen-activated protein kinase and Akt
signaling pathways [8,9,11]; it up-regulates ﬁbroblast growth factor-2
in an Erk1/2-dependent manner [10] and it enhances IL-6 expression
through STAT3 activation, which promotes angiogenesis [28]. Al-
though the activation of Akt signaling by visfatin is well established,
the events occurring downstream of Akt activation remain unex-
plored [8,9,11]. We have now demonstrated for the ﬁrst time that
visfatin activates mTOR signaling and inactivates GSK3β signaling in
human endothelial cells, thereby enhancing VEGF and cyclin D1
expression in these cells.
ThemTOR protein is a serine/threonine kinase that plays a key role
in cell growth and homeostasis. Hypoxia activates the mTOR pathway
to promote angiogenesis and cell proliferation [22,29]. Several studies
have found that the activation of PI3-kinase and the subsequent
activation of mTOR enhance the expression of HIF1-dependent genes,
including VEGF [21–23]. HIF1 is a heterodimeric transcription factor
composed of the inducible and constitutively expressed subunits
HIF1α and HIF1β, respectively [21]. Under hypoxic conditions, mTOR
activation enhances the activity of HIF1α by inhibiting proteolytic
degradation, resulting in elevated VEGF expression; this effect is
reversible by rapamycin [21,23]. Since mTOR activation is needed to
prevent HIF1α degradation, HIF1α seems to be increased after 30 min
of visfatin treatment (Fig. 1).The mTOR protein has three phosphorylation sites, Ser-2446, Ser-
2448, and Ser-2481. Ser-2448 phosphorylation, which is usually
induced by insulin, correlates with mTOR activation [30–32] and, in
our study, was increased by visfatin. Thus, the induction of mTOR Ser-
2448 phosphorylation by visfatin indicates that visfatin activates the
mTOR pathway, which is also demonstrated by the increased
phosphorylation of p70S6K at Thr-389 (Fig. 3B). Although mTOR has
long been known to be phosphorylated at Ser-2448 via the PI3-
kinase/Akt signaling pathway, p70S6K was recently revealed to be
the major protein kinase responsible for this phosphorylation [24].
In accordance with the results of Chiang et al. [24], we found that
p70S6K knockdown abolished the visfatin-induced increase in mTOR
Ser-2448 phosphorylation and VEGF expression (Fig. 3D). Thus, the
mTOR pathway is important in the induction of VEGF expression by
visfatin in endothelial cells.
GSK3β is a serine/threonine kinase that plays important roles in
metabolism, embryonic development, and tumorigenesis [33]. GSK3β
has two sites of reversible phosphorylation: an inhibitory site (Ser-9)
and an activating site (Tyr-216). Visfatin-induced phosphorylation of
GSK3β at Ser-9 thus leads to the inactivation of GSK3β (Fig. 1). The
phosphorylation of β-catenin at Ser-37, Ser-33, and Thr-41 by GSK3β
results in the ubiquitination and degradation of β-catenin. The recent
ﬁnding that β-catenin induces the expression of VEGF-A and VEGF-C
implicates β-catenin in angiogenesis [33,34]. In our study, β-catenin
knockdown diminished visfatin-induced cell proliferation and tube
formation (Fig. 5). β-catenin has been reported to play dual roles in
cells; it maintains cell architecture and polarity at adherens junctions
and it translocates into the nucleus to increase the expression of
Visfatin
Akt
mTOR
p70S6K
HIF1α
VEGF
GSK3β
β-Catenin
Angiogenesis, Cell Proliferation
Cyclin D1
Fig. 7. Proposed scheme for the signaling pathways involved in visfatin-induced
angiogenesis. See Discussion for details. The dotted arrow indicates a pathway that
remains to be elucidated.
Fig. 6. The PI3-kinase/Akt signaling pathway is involved in visfatin-induced mTOR
activation and GSK3β inactivation. HUVECs were pretreated with the PI3-kinase
inhibitor LY294002 (20 μM), incubated with visfatin (300 ng/ml) for 4 h, and analyzed
for levels of the indicated proteins by Western blotting. Results shown are
representative of at least three independent experiments.
770 J.-W. Park et al. / Biochimica et Biophysica Acta 1813 (2011) 763–771various genes, including c-myc and cyclin D1 [26,33]. In unstimulated
endothelial cells, β-catenin primarily localizes at the cell membrane,
but visfatin induces its nuclear translocation, leading to increased
expression of cyclin D1 (Fig. 4C). In addition, β-catenin knockdown
diminishes cyclin D1 and VEGF expressions, thereby inhibiting the
induction of an angiogenic phenotype by visfatin (Fig. 5).
Interestingly, visfatin-induced GSK3β phosphorylation at Ser-9
depends on the mTOR pathway (Fig. 4A, B). Our results are consistent
with those of Zhang et al. [25], who reported that GSK3β can be
regulated downstream of mTOR complex 1 and that p70S6K, rather
than Akt, is the predominant GSK3β regulatory kinase, particularly
under conditions of continuous activation of the mTOR pathway [25].
In other words, activation of mTOR signaling by visfatin contributes to
GSK3β inactivation in human endothelial cells.
In contrast, GSK3β inhibition can result in mTOR activation
according to Inoki et al. [34]. We therefore investigated the effect of
visfatin-induced inactivation of GSK3β on mTOR activation using DIF-
3 and LiCl to induce GSK3β activation and inactivation, respectively
(Supplementary Fig. 2) [26,35]. LiCl pretreatment did not affect
visfatin-induced mTOR activation, but DIF-3 pretreatment diminished
this activation (Supplementary Fig. 2A) and inhibited visfatin-induced
tube formation (Supplementary Fig. 2B). In immunocytochemical
experiments, neither DIF-3 nor LiCl treatment were found to increase
caspase-3 cleavage (Supplementary Fig. 2C), suggesting that angio-
genic inhibition by DIF-3 is not attributable to apoptosis induction.
TUNEL assay yielded similar results (data not shown). This ﬁnding is
consistent with that reported by Takahashi-Yanaga et al. [35]. Thus,
the effects of visfatin on mTOR and GSK3βmay result from reciprocal
regulation. Further studies are needed to conﬁrm this hypothesis.
It is still unknown whether the exogenous visfatin initiated the
angiogenic effects via cellular surface receptor or intracellular target.
Thus, we measured both intracellular and extracellular visfatin levels
after visfatin treatment in HUVECs (Supplementary Fig. 3). After
visfatin treatment for 30 min, visfatin levels in medium were
increased in a dose-dependent manner, while visfatin levels were
not signiﬁcantly increased in cell lysates. In contrast, visfatin levels
were not signiﬁcantly changed in medium after visfatin treatment for
24 h, while visfatin levels were signiﬁcantly increased in cell lysates
(Supplementary Fig. 3A, B). These results indicate that exogenous
visfatin may penetrate the membrane and directly function inside
cells after 24 h. However, the activation of signalingmolecules such as
Akt, mTOR, and GSK3β already occurred after 30 min of visfatin
treatment (Fig. 1A, B). Thus, the activation of signaling molecules by
visfatin in the present study may occur via cellular surface receptor.
Visfatin plays a key role in the salvage pathway for NAD+
biosynthesis. It has been demonstrated that a speciﬁc competitive
inhibitor of visfatin, FK866, causes cellular NAD+ depletion, and hasanti-angiogenic activity in murine renal cell carcinoma [36,37]. We
examined the effect of FK866 on visfatin-induced angiogenesis in vitro
and ex vivo (Supplementary Fig. 4A, B). Interestingly, FK866 could
abolish the angiogenic effects of visfatin in vitro and ex vivo. Thus, NAD+
levels seem to be important for visfatin-induced angiogenesis. Corre-
lation between signalingpathways andNAD+levels in visfatin-induced
angiogenesis needs to be further elucidated.
In the present study, visfatin induced angiogenesis at concentra-
tions higher than 300 ng/ml similar to the previous studies [9,10,28].
Although plasma visfatin concentrations in humans are usually
b100 ng/ml, visfatin concentrations in tissues such as cancer and
adipose tissues can be much higher. In addition, exogenous visfatin
could enter into cells as shown in Supplementary Fig. 3.
Visfatin also has a reported association with inﬂammation [38],
which is closely linked to angiogenesis through a mechanism that is
not well understood [39]. The possibility that visfatin plays a key role
in bridging the gap between angiogenesis and inﬂammation is
another reason that understanding the mechanism by which visfatin
promotes angiogenesis is critically important.
Previous studies have reported that the PI3-kinase/Akt signaling
pathway is an important regulator of visfatin-induced angiogenesis
[9,11]. In the present study, we showed that mTOR and GSK3β
signaling is involved in the effects of visfatin on angiogenesis. Taken
together (see Fig. 7), our results demonstrate that visfatin-induced
angiogenesis requires mTOR and GSK3β signaling downstream of the
PI3-kinase/Akt signaling pathway. Inhibition of PI3-kinase by the
inhibitor LY293002 also inhibits visfatin-induced activation of mTOR
and visfatin-induced inactivation of GSK3β. Activation of mTOR
inactivates GSK3β, which promotes the nuclear translocation of β-
catenin, thereby increasing the expression of cyclin D1 and VEGF. In
contrast, GSK3β inactivation may also activate mTOR. Activation of
mTOR also increases HIF1α and VEGF expression in endothelial cells.
Collectively, these results show that the activation of mTOR and the
inactivation of GSK3β play key roles in visfatin-induced angiogenesis.
The HIF1α and β-catenin transcription factors are known to regulate
VEGF expression, and both were upregulated by visfatin exposure in
our experiments using endothelial cells (Fig. 1), suggesting that HIF1α
and β-catenin may physically interact with each other to enhance
VEGF expression. Further studies are needed to elucidate the precise
mechanism underlying this putative interaction and to determine
which transcription factor plays an executive role in VEGF expression.
771J.-W. Park et al. / Biochimica et Biophysica Acta 1813 (2011) 763–771In conclusion, our data provide the ﬁrst evidence that visfatin-
inducedmTOR activation and GSK3β inactivation play important roles
in visfatin-induced angiogenesis. Furthermore, visfatin increases
HIF1α and β-catenin expressions, leading to increased expression of
VEGF and cyclin D1. Our ﬁndings demonstrate that visfatin and these
pro-angiogenic factors are engaged in functional crosstalk via the
mTOR and GSK3β pathways. This newly identiﬁed mechanism of
visfatin signaling provides novel insights into the diverse effects of
visfatin and will enhance understanding of its functional roles in
human diseases.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.02.009.
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